Recent executive actions have accelerated aspects of federal cannabis policy, with the Department of Justice and DEA issuing a final order in April 2026 that immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act, effective late that month. This followed a December 2025 executive order directing expedited rulemaking. Broader rescheduling of all marijuana from Schedule I remains under review through an expedited DEA administrative hearing scheduled to begin June 29, 2026, with proceedings set to conclude by mid-July. Trader consensus reflected in current market pricing assigns limited probability to full rescheduling by year-end, consistent with the procedural timeline and the distinction between immediate medical categories and comprehensive changes affecting recreational use.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$758,923 Vol.
June 30
2%
December 31
24%
$758,923 Vol.
June 30
2%
December 31
24%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent executive actions have accelerated aspects of federal cannabis policy, with the Department of Justice and DEA issuing a final order in April 2026 that immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act, effective late that month. This followed a December 2025 executive order directing expedited rulemaking. Broader rescheduling of all marijuana from Schedule I remains under review through an expedited DEA administrative hearing scheduled to begin June 29, 2026, with proceedings set to conclude by mid-July. Trader consensus reflected in current market pricing assigns limited probability to full rescheduling by year-end, consistent with the procedural timeline and the distinction between immediate medical categories and comprehensive changes affecting recreational use.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions